Comparative hematological profiles for dose-dense vs. regular anthracycline-based neoadjuvant chemotherapy in non-metastatic breast cancer

Exp Ther Med. 2021 Jul;22(1):747. doi: 10.3892/etm.2021.10179. Epub 2021 May 11.ABSTRACTThe aim of the present study was to examine both the feasibility and toxicity of neoadjuvant dose-dense chemotherapy in women with non-metastatic breast cancer. A search within the OncoHelp Association breast cancer database has been performed in order to identify all non-metastatic breast cancer patients who underwent an initial consultation with a medical oncologist between March 2016 and April 2020. The inclusion criteria used were: i) Age, ii) follow-up care obtained at OncoHelp Association, iii) the intent to treat with a neoadjuvant dose-dense anthracycline every two weeks for four cycles (C1-C4) followed by paclitaxel every two weeks for four cycles, with white blood cell growth factor support, and iv) regular anthracycline-based chemotherapy every three weeks for four cycles, followed by paclitaxel every three weeks for four cycles, v) weight, vi) height, vii) Eastern Cooperative Oncology Group (ECOG) performance status, viii) hemoglobin (Hb) level, ix) Platelet count and x) neutrophil count.PMID:34055062 | PMC:PMC8138269 | DOI:10.3892/etm.2021.10179

Source: Experimental and Therapeutic Medicine - May 31, 2021 Category: General Medicine Authors: Dorel Popovici Cristina Oprean Sorin S ăftescu Alina Negru Mihnea Munteanu Horia T Stanca Adrian Teodoru Simona Stanca Șerban Negru Source Type: research